Filipino - Kiingereza - FDA (Food And Drug Administration)

astrazeneca pharmaceuticals (phils.), inc. - goserelin acetate ( equivalent to goserilin base) - depot soloution for subcutaneous injection - 10.8mg

Filipino - Kiingereza - FDA (Food And Drug Administration)

astrazeneca pharmaceuticals (phils.), inc. - goserelin acetate ( equivalent to goserilin base) - depot soloution for subcutaneous injection - 10.8mg

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - goserelin acetate - implant - 3.6 base milligrams - goserelin

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - goserelin acetate - implant - 10.8 base milligrams - goserelin

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - goserelin acetate 12.5mg equivalent to 10.8 mg goserelin - subcutaneous implant - 10.8 mg - active: goserelin acetate 12.5mg equivalent to 10.8 mg goserelin excipient: poly(lactide) polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - goserelin acetate 4.1mg equivalent to 3.6 mg goserelin - subcutaneous implant - 3.6 mg - active: goserelin acetate 4.1mg equivalent to 3.6 mg goserelin excipient: polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

profind wholesale ltd - goserelin acetate - implant - 10.8 base milligrams

Singapoo - Kiingereza - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - goserelin acetate eqv peptide - injection - 3.6 mg/syringe - goserelin acetate eqv peptide 3.6 mg/syringe

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;  ; bicalutamide 50mg - combination - 10.8mg+50mg pack - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;  ; bicalutamide 50mg;   - combination - 3.6mg + 50mg pack - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin active: bicalutamide 50mg   excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.